The development of a bead-based multiplex immunoassay for the detection of IgG antibodies to CMV and EBV.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
TitleThe development of a bead-based multiplex immunoassay for the detection of IgG antibodies to CMV and EBV.
Published inJ Immunol Methods 2018; 462:1-8
PubliekssamenvattingLatent infection with Cytomegalovirus (CMV) or Epstein-Bar virus (EBV) is associated with compromised immune responses. The commercially available ELISA-kits provide a semi-quantitative or qualitative detection of IgG antibodies against either CMV or EBV. To reduce the amount of sample needed and improve throughput and range of quantitation compared to ELISAs, a multiplex immunoassay (MIA) for the simultaneous quantitative detection of antibodies against CMV and two antigens of EBV (EBV capsid antigen (EBV-VCA) and EBV nuclear antigen 1 (EBNA-1)) was developed and standardized. Our assay shows a good correlation with the separate ELISAs, has a high specificity and is much more sensitive than the ELISAs. The MIA allows faster analysis of samples and can be combined with the MIA for detection of antibodies to measles, mumps, rubella and varicella zoster (MMRV) as published previously. In conclusion, the CMV-EBV MIA is a reliable assay that allows for more efficient detection of specific antibodies to CMV and EBV. This MIA therefore is especially useful for large-scale surveillance studies.
- Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.
- Authors: Smits GP, van Gageldonk PG, Schouls LM, van der Klis FR, Berbers GA
- Issue date: 2012 Mar
- Evaluation of a multiplex flow immunoassay for detection of epstein-barr virus-specific antibodies.
- Authors: Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Beito EM
- Issue date: 2008 Sep
- Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
- Authors: Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B
- Issue date: 2014 Jun
- Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
- Authors: Grandjean Lapierre S, Vallières E, Rabaamad L, Labrecque M, Chartrand C, Renaud C
- Issue date: 2016 Aug
- Virus-specific antibodies to Epstein-Barr virus, varicella-zoster virus and rubella virus in renal transplant patients with cytomegalovirus infections.
- Authors: O'Neill HJ, Shirodaria PV
- Issue date: 1992 May